HyperMed Imaging, Inc. announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for the company’s new medical imaging device called HyperView™. The HyperView product is a handheld, battery operated, portable diagnostic imaging device that is used to assess tissue oxygenation without contacting the patient
Sanofi (EURONEXT: SAN and NYSE: SNY), a global healthcare leader and JHL Biotech, Inc. (6540.TWO), a biopharmaceutical company with development and manufacturing facilities in Wuhan and Taiwan, announced today a strategic alliance to collaborate on the development and commercialization of biological therapeutics in China and with potential international expansion.
Scientific Publication by a Group Including Juno Therapeutics Scientific Co-Founder Michel Sadelain Is Featured in Endpoints News Article
CAR-Ts won’t be on the market before next year, but the technology arms race inspired by the prospect of a multibillion-dollar market has inspired a group of prominent investigators to design a new, 3.0 model in the lab that includes a built-in checkpoint mechanism. And it worked like a charm in mouse models of solid tumors - a critical hurdle that the key players have been struggling to clear.
JHL Biotech (TWEM: 6540) and GE Healthcare’s Life Sciences business (NYSE: GE) are proud to announce mechanical completion of JHL Biotech’s JHL-1 biopharmaceutical manufacturing facility in the Biolake area of Wuhan, China.
JHL Biotech Intends to Manufacture Biosimilars in Its New Facility, the Company Is Featured in Fierce Pharma Manufacturing and Bloomberg Articles
First prefab biologics plant goes up in China, in 11 days. JHL Biotech intends to manufacture biosimilars in its new facility.
(GenomeWeb) – Strand Life Sciences is aiming to position its 152-gene cancer sequencing test for solid tumors as a tool that can be used early on in a patient's disease in order to inform first-line therapy.
JHL Biotech (TWEM: 6540), an emerging biosimilars company incorporated in Cayman Islands and based in Taiwan and China, announced today it has been publicly listed on the Taiwan Emerging Stock Board, effective September 17, 2015.
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's Biologics License Application (BLA) for RI-002 intended for the primary immunodeficiency (PI) population.
JHL Biotech, Inc., an emerging biopharmaceutical company, today announced that it has closed a Series C fundraising of $45.6 million, led by funds managed by a global renowned crossover fund with over US$1.6 trillion in AUM, with participation from existing investor Milestone Capital and new investors Sungent BioVenture and Liwick Investment Management.
Opus Bio, Inc., today announced that Juno Therapeutics, Inc. has entered into an agreement to obtain a license for the company’s CAR-T cell product candidate targeting CD22, a protein expressed on most B cell leukemias and lymphomas.
ADMA Biologics Announces Positive Top-Line Phase III Data for Primary Immune Deficiency Disease (PIDD) Patients
ADMA Biologics, Inc. (Nasdaq:ADMA) today announced its lead product candidate RI-002 has demonstrated positive Phase III results and successfully achieved its primary endpoint.
ADMA Biologics, Inc. (OTCQB:ADMA) today announced that the NASDAQ stock market has approved ADMA's common stock for listing on the NASDAQ Capital Market and is expected to begin trading on November 10, 2014 under the symbol "ADMA."
Alcon to acquire WaveTec® Vision, developer of first commercialized intra-operative guidance system for enhanced cataract outcomes
Alcon, the global leader in eye care and the second largest division of Novartis Group, announced today that the company has entered into an agreement to acquire WaveTec Vision.
Lentigen Corporation Announces Sale of Lentiviral Vector Manufacturing Business and Change of Name to Opus Bio, Inc.
Lentigen Corporation, a global leader in lentiviral technology for cell and gene therapy applications, today announced the sale of its lentiviral vector manufacturing business and related assets to Miltenyi Biotec, who will operate through its newly formed, wholly-owned US subsidiary Lentigen Technology, Inc.
Strand Life Sciences Pvt. Ltd. and Health Care Global Enterprises Ltd. are proud to announce the launch of The Strand Triesta Center For Cancer Genomics at a symposium on Clinical Genomics: New Generation Cancer Care.
HealthCare Global (HCG) Enterprises Ltd, The Specialists in Cancer Care, creates a new benchmark in cancer care by making genomics-based diagnostics, a ‘standard-of-care’ for cancer treatment in India. These diagnostic tests will support physicians, and their patients with the most accurate and advanced tumor profiling of large number genes for “actionable” mutations. The information about these mutations helps to identify targeted therapies and treatment choices early in the course of cancer care.
Curie-Cancer, the body responsible for developing Institut Curie's industry partnership activity, and Strand Scientific Intelligence, Inc. (Strand) announce the launch of the Curie Image Database (CID), a breakthrough image analysis and management platform that they developed jointly over the last two years at the Cell and Tissue Imaging Core Facility of the Institut Curie (PICT-IBiSA).
Strand Life Sciences to partner with US based El Camino Hospital to set up Strand Center for Genomics and Personalized Medicine
Strand Life Sciences Private Limited, a global life sciences company headquartered in Bangalore, is collaborating with the San Francisco Bay Area based El Camino Hospital to locate a Strand Center for Genomics and Personalized Medicine at the Genomic Medicine Institute of the El Camino Hospital to accelerate the adoption of next generation sequencing based research panels and counseling services by the physicians at the Hospital and its partner clinics.
Strand Life Sciences, a bioinformatics company whose products for Array, Mass Spec and NGS analysis are used by over 2000 laboratories worldwide and has recently developed solutions in the field of clinical diagnostics, is launching its Early Access Program for its clinical genomics interpretation and reporting platform. Strand’s clinical application is a deep interpretation and reporting system for clinical genomics. It was designed in collaboration with clinicians while working on real patient cases in Strand’s clinical laboratory, and therefore provides the necessary information to help medical practitioners confidently deliver clinical reports with ease.